Suppr超能文献

通过慢病毒TTR-YapERT2转导的肝细胞并使用他莫昔芬控制Yap亚细胞定位实现成功肝细胞治疗的实验模型

Experimental Model for Successful Liver Cell Therapy by Lenti TTR-YapERT2 Transduced Hepatocytes with Tamoxifen Control of Yap Subcellular Location.

作者信息

Yovchev Mladen, Jaber Fadi L, Lu Zhonglei, Patel Shachi, Locker Joseph, Rogler Leslie E, Murray John W, Sudol Marius, Dabeva Mariana D, Zhu Liang, Shafritz David A

机构信息

Marion Bessin Liver Research Center, Division of Gastroenterology and Liver Diseases, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.

Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.

出版信息

Sci Rep. 2016 Jan 14;6:19275. doi: 10.1038/srep19275.

Abstract

Liver repopulation by transplanted hepatocytes has not been achieved previously in a normal liver microenvironment. Here we report that adult rat hepatocytes transduced ex vivo with a lentivirus expressing a human YapERT2 fusion protein (hYapERT2) under control of the hepatocyte-specific transthyretin (TTR) promoter repopulate normal rat liver in a tamoxifen-dependent manner. Transplanted hepatocytes expand very slowly but progressively to produce 10% repopulation at 6 months, showing clusters of mature hepatocytes that are fully integrated into hepatic parenchyma, with no evidence for dedifferentiation, dysplasia or malignant transformation. Thus, we have developed the first vector designed to regulate the growth control properties of Yap that renders it capable of producing effective cell therapy. The level of liver repopulation achieved has significant translational implications, as it is 2-3x the level required to cure many monogenic disorders of liver function that have no underlying hepatic pathology and is potentially applicable to diseases of other tissues and organs.

摘要

在正常肝脏微环境中,此前尚未实现移植肝细胞对肝脏的再填充。在此我们报告,用慢病毒在体外转导成年大鼠肝细胞,该慢病毒在肝细胞特异性甲状腺转运蛋白(TTR)启动子的控制下表达人YapERT2融合蛋白(hYapERT2),这些肝细胞以他莫昔芬依赖的方式在正常大鼠肝脏中实现再填充。移植的肝细胞扩张非常缓慢,但逐渐增加,在6个月时产生10%的再填充,显示出成熟肝细胞簇完全整合到肝实质中,没有去分化、发育异常或恶性转化的迹象。因此,我们开发了第一种旨在调节Yap生长控制特性的载体,使其能够产生有效的细胞治疗。所实现的肝脏再填充水平具有重要的转化意义,因为它是治愈许多无潜在肝脏病理的单基因肝功能障碍所需水平的2至3倍,并且可能适用于其他组织和器官的疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee54/4725878/48ea95e3dd47/srep19275-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验